IL158774A0 - An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases - Google Patents

An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases

Info

Publication number
IL158774A0
IL158774A0 IL15877402A IL15877402A IL158774A0 IL 158774 A0 IL158774 A0 IL 158774A0 IL 15877402 A IL15877402 A IL 15877402A IL 15877402 A IL15877402 A IL 15877402A IL 158774 A0 IL158774 A0 IL 158774A0
Authority
IL
Israel
Prior art keywords
adenosine
combination
receptor agonist
anticholinergic agent
obstructive airways
Prior art date
Application number
IL15877402A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129275A external-priority patent/GB0129275D0/en
Priority claimed from GB0210238A external-priority patent/GB0210238D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of IL158774A0 publication Critical patent/IL158774A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15877402A 2001-05-25 2002-05-24 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases IL158774A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29384201P 2001-05-25 2001-05-25
GB0129275A GB0129275D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination
GB0210238A GB0210238D0 (en) 2002-05-03 2002-05-03 Pharmaceutical composition
PCT/EP2002/005725 WO2002096462A1 (en) 2001-05-25 2002-05-24 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases

Publications (1)

Publication Number Publication Date
IL158774A0 true IL158774A0 (en) 2004-05-12

Family

ID=27256345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15877402A IL158774A0 (en) 2001-05-25 2002-05-24 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases

Country Status (22)

Country Link
US (1) US20040171576A1 (xx)
EP (1) EP1395287A1 (xx)
KR (1) KR20030097901A (xx)
CN (1) CN1535161A (xx)
AP (1) AP2003002911A0 (xx)
BG (1) BG108383A (xx)
BR (1) BR0209986A (xx)
CA (1) CA2448086A1 (xx)
CO (1) CO5540324A2 (xx)
CZ (1) CZ20033126A3 (xx)
EE (1) EE200300586A (xx)
HU (1) HUP0400029A2 (xx)
IL (1) IL158774A0 (xx)
MA (1) MA27028A1 (xx)
MX (1) MXPA03010787A (xx)
NO (1) NO20035202D0 (xx)
OA (1) OA12609A (xx)
PA (1) PA8546101A1 (xx)
PL (1) PL366899A1 (xx)
SK (1) SK14302003A3 (xx)
SV (1) SV2003001055A (xx)
WO (1) WO2002096462A1 (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
SG176313A1 (en) 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
CA2576826C (en) 2004-08-02 2014-09-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
RU2009115954A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
ATE331726T1 (de) * 1998-10-16 2006-07-15 Pfizer Adenine-derivate
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
PA8546101A1 (es) 2003-12-10
PL366899A1 (en) 2005-02-07
AP2003002911A0 (en) 2003-12-31
MA27028A1 (fr) 2004-12-20
BG108383A (bg) 2004-08-31
HUP0400029A2 (hu) 2004-04-28
EP1395287A1 (en) 2004-03-10
EE200300586A (et) 2004-04-15
WO2002096462A1 (en) 2002-12-05
MXPA03010787A (es) 2004-03-02
CN1535161A (zh) 2004-10-06
KR20030097901A (ko) 2003-12-31
OA12609A (en) 2006-06-09
SV2003001055A (es) 2003-11-14
SK14302003A3 (sk) 2004-08-03
CO5540324A2 (es) 2005-07-29
CZ20033126A3 (cs) 2004-09-15
US20040171576A1 (en) 2004-09-02
NO20035202D0 (no) 2003-11-24
CA2448086A1 (en) 2002-12-05
BR0209986A (pt) 2004-04-06

Similar Documents

Publication Publication Date Title
IL158774A0 (en) An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
AU2003273300A8 (en) Modified glp-1 receptor agonists and their pharmacological methods of use
HUP0401191A3 (en) Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
HK1042236A1 (zh) 用於治療咳嗽的痛啡肽(nociceptin)受體orl-1激動劑
IL130424A (en) Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis
EP1210063A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING THE ABSORPTION OF HYDROPHILIC THERAPEUTIC ACTIVE SUBSTANCES
EG24137A (en) Tropane derivatives useful in therapy
ZA200503645B (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
IL158776A0 (en) A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
AU2002314110A1 (en) Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
HUE039348T2 (hu) A2A receptor antagonisták mozgási rendellenességek kezelésében történõ alkalmazásra
IL211288A0 (en) Vaginally administered anti-dysrhythmic agents for treating pelvic pain and infertility
IL161572A0 (en) Adenosine a2a receptor antagonists
HK1063780A1 (en) Adenosine a2a receptor antagonists
IL149495A0 (en) Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy
AU5977501A (en) Method for treating retinal degeneration with purinergic receptor agonists
EP1471819A4 (en) COMPOSITION AND IMAGING METHODS FOR PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF A THERAPEUTIC DELIVERY SYSTEM
ZA200308465B (en) An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
PL359222A1 (en) Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1 receptors and/or dopamine d2 receptors
HUP0402540A3 (en) Pharmaceutical combinations of adenosine a-2a and betha-2-adrenergic receptor agonists
EP1427429A4 (en) COMPOSITIONS AND METHODS FOR TREATING HYPERGLYCEMIA SUBJECTS
EP1371371A4 (en) USE OF N-ACETYL-D-GLUCOSAMINE IN THE PRODUCTION OF A PHARMACEUTICAL AGENT FOR THE PREVENTION AND TREATMENT OF SEXUAL DISORDERS
GB0201284D0 (en) Screening methods for contraceptive and fertility agents
IS7012A (is) Adenósín A2A viðtaka gerandefni og and-kólínergurmiðill í blöndu til meðhöndlunar á teppandi kokrennusjúkdómum
EP1316559A4 (en) ADENOS DERIVATIVES AND THEIR USE